Kanghyug Choi1, Hee Yoon Jang1, Joong Mo Ahn2, Sung Ho Hwang3, Jung Wha Chung4, Yun Suk Choi1, Jin-Wook Kim1, Eun Sun Jang1, Gwang Hyeon Choi1, Sook-Hyang Jeong1. 1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. 2. Department of Radiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. 3. Department of Nursing, Daewon Univeristy College, Jecheon, Korea. 4. Department of Internal Medicine, Wonkwang University Sanbon Hospital, Sanbon, Korea.
Abstract
Background/Aims: The role of serum myokine levels in sarcopenia and the outcome of hepatocellular carcinoma (HCC) patients are not clear. This study investigated the serum levels of myostatin, follistatin, and interleukin-6 (IL-6) in HCC patients and their association with sarcopenia and survival. Methods: Using prospectively collected pretreatment samples from 238 HCC patients in a hospital from 2012 to 2015, the serum levels of 3 myokines were determined and compared to 50 samples from age and sex-matched healthy controls. Sarcopenia was evaluated using the psoas muscle index (PMI) measured at the third lumbar level in the computed tomography, and clinical data were collected until 2017. Results: The median levels of the 3 myokines for the male and female HCC patients were as follow: myostatin (3,979.3 and 2,976.3 pg/mL), follistatin (2,118.5 and 2,174.6 pg/mL), and IL-6 (2.5 and 2.7 pg/mL), respectively. Those in the HCC patients were all significantly higher than in the healthy controls. In the HCC patient, the median PMI was 4.43 (males) and 2.17 cm2/m2 (females) with a sarcopenic prevalence of 56.4%. The serum levels of myostatin, IL-6 and follistatin in the HCC patients showed a positive, negative, and no correlation with PMI, respectively. The serum follistatin level was an independent factor for poor survival in HCC patients. Conclusions: The serum levels of myostatin, follistatin, and IL-6 and their correlation with sarcopenia and survival were presented in HCC patients for the first time. The role of the serum follistatin level as a poor prognostic biomarker warrants further study.
Background/Aims: The role of serum myokine levels in sarcopenia and the outcome of hepatocellular carcinoma (HCC) patients are not clear. This study investigated the serum levels of myostatin,follistatin, and interleukin-6 (IL-6) in HCCpatients and their association with sarcopenia and survival. Methods: Using prospectively collected pretreatment samples from 238 HCCpatients in a hospital from 2012 to 2015, the serum levels of 3 myokines were determined and compared to 50 samples from age and sex-matched healthy controls. Sarcopenia was evaluated using the psoas muscle index (PMI) measured at the third lumbar level in the computed tomography, and clinical data were collected until 2017. Results: The median levels of the 3 myokines for the male and female HCCpatients were as follow: myostatin (3,979.3 and 2,976.3 pg/mL), follistatin (2,118.5 and 2,174.6 pg/mL), and IL-6 (2.5 and 2.7 pg/mL), respectively. Those in the HCCpatients were all significantly higher than in the healthy controls. In the HCCpatient, the median PMI was 4.43 (males) and 2.17 cm2/m2 (females) with a sarcopenic prevalence of 56.4%. The serum levels of myostatin,IL-6 and follistatin in the HCCpatients showed a positive, negative, and no correlation with PMI, respectively. The serum follistatin level was an independent factor for poor survival in HCCpatients. Conclusions: The serum levels of myostatin,follistatin, and IL-6 and their correlation with sarcopenia and survival were presented in HCCpatients for the first time. The role of the serum follistatin level as a poor prognostic biomarker warrants further study.
Authors: Sojung Han; Hye Jin Choi; Seung-Hoon Beom; Hye Rim Kim; Hyein Lee; Jae Seung Lee; Hye Won Lee; Jun Yong Park; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Jinsil Seong; Jong Yun Won; Beom Kyung Kim Journal: J Cancer Res Clin Oncol Date: 2021-04-23 Impact factor: 4.553